Hurdles in treating Hurler disease: potential routes to achieve a “real” cure

• Published in: Blood advances 2020-06, Vol.4 (12), p.2837-2849
• Main Authors: van den Broek, Brigitte T.A., van Doorn, Jaap, Hegeman, Charlotte V., Nierkens, Stefan, Lindemans, Caroline A., Verhoeven-Duif, Nanda, Boelens, Jaap Jan, van Hasselt, Peter M.
• Format: Article
• Language: English
• Subjects: Blood-Brain Barrier; Enzyme Replacement Therapy; Hematopoietic Stem Cell Transplantation; Humans; Mucopolysaccharidoses; Mucopolysaccharidosis I - therapy; Review
• ISSN: 2473-9529; 2473-9537
• DOI: 10.1182/bloodadvances.2020001708

Mucopolysaccharidoses (MPSs) are multiorgan devastating diseases for which hematopoietic cell transplantation (HCT) and, to a lesser extent, enzyme replacement therapy have substantially altered the course of the disease. Furthermore, they have resulted in increased overall survival, especially for Hurler disease (MPS-1). However, despite the identification of clinical predictors and harmonized transplantation protocols, disease progression still poses a significant burden to patients, although at a slower pace. To design better therapies, we need to understand why and where current therapies fail. In this review, we discuss important aspects of the underlying disease and the disease progression. We note that the majority of progressive symptoms that occur in “hard-to-treat” tissues are actually tissues that are difficult to reach, such as avascular connective tissue or tissues isolated from the circulation by a specific barrier (eg, blood-brain barrier, blood-retina barrier). Although easily reached tissues are effectively cured by HCT, disease progression is observed in these “hard-to-reach” tissues. We used these insights to critically appraise ongoing experimental endeavors with regard to their potential to overcome the encountered hurdles and improve long-term clinical outcomes in MPS patients treated with HCT.